The Zydus Group on Wednesday said it has received the US Food and Drug Administration's (USFDA) approval for the Phase I clinical trial of Zydpla 1, a next generation anti-diabetic solution. Zydpla 1 is an orally active, small molecule New Chemical Entity ... Business Line, 1 month ago
Zydus gets USFDA nod for clinical trial anti-diabetes molecule - Business Line, 1 month ago
Zydus gets USFDA nod for phase-I clinical trial of diabetes drug - Business Standard India, 1 month ago
3 images for "zydus group"
Three months after announcing a breakthrough in research, the Zydus Group on Tuesday announced the launch of Lipaglyn, a novel drug targeted at diabetes not controlled by statins alone. This is expected to meet a healthcare need for treating diabetic ...Business Line, 2 months ago Zydus announces USFDA approval for initiating Phase I clinical trials of ZYDPLA1 Money Control, 1 month ago Zydus announces US FDA approval for initiating Phase I clinical trials of "ZYDPLA1" ? a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes Noodls, 1 month ago Zydus launches diabetes treatment drug Lipaglyn Business Line, 2 months ago
More from: Myiris, Myiris...and 1 other sources
Contract won the business after a multi-agency pitch. The incumbent agency was Rediffusion Zydus Wellness Ltd, the consumer products arm of the Ahmedabad-headquartered Zydus Cadila pharma group, has awarded the creative mandate of its flagship ...Best Media Info, 2 weeks ago Contract bags creative duties of Sugar Free Agencyfaqs!, 3 weeks ago
AHMEDABAD: Ahmedabad-based drug maker Zydus Cadila's net profit was up by 94% for second quarter ended September 30, 2013. The net profit and total income from operations stood at Rs 183.3 crore and Rs 1753 crore respectively. During the quarter, ...Economic Times, 1 month ago CADILA HEALTHCARE LIMITED : Zydus Cadila registers 94% increase in Net Profit in Q2 4 Traders, 1 month ago Zydus Cadila and Pieris AG Enter into Co-Development Agreement for Novel Anticalin Therapeutics [Professional Services Close - Up] Pharmacy Choice, 1 month ago Cadila Healthcare Q2 net profit up 82% Sify, 1 month ago
Pharmaceutical firm Zydus Cadila on Wednesday said it has entered into a drug development and commercialisation alliance with Germany's Pieris AG for a new therapeutic protein molecule branded Anticalin. The collaboration combines Pieris' drug ...The Hindu, 1 month ago Zydus ties up with German co Pieris for drug development Hindu Business Line, 1 month ago Cadila and Pieris create drug development partnership MedCity News, 1 month ago
More from: , Jagran Post...and 2 other sources
Satish Khanna, Director, Valmax Corporate Services and Ex Group President of Lupin India, elaborates on the various approaches that can be implemented by pharma firms to prevent stagnation and pave the way for further growth Pharmaceutical market ...Express Pharma, 1 month ago
Zydus Wellness Ltd, a leading FMCG company in India's consumer wellness space, has appointed chef Sanjeev Kapoor as its brand ambassador. He will now promote the company's two flagship brands: Sugar Free, a sugar substitute, and Nutralite, a ...FnBnews.com, 5 days ago Sanjeev Kapoor named brand ambassador of two of Zydus Wellness largest brands, Sugar Free and Nutralite This Week Bangalore, 1 week ago
It's earnings season. www.indiainfoline.com, a part of the IIFL Group, presents you real-time, comprehensive, and in-depth analysis of company earnings to give you that investment edge. The 'Results Calendar' helps you keep track of all important results. The ...India Infoline, 1 month ago
Data for 800 companies from Bombay Stock Exchange. Values are: days closing price, previous closing price in brackets, 52-week low and high in bold, and volume traded (in 000) in brackets. GROUP A A A B B 701.65(670.35) 737-448 (105) A C C 1106.9(1100.0) ...Deccan Herald, 5 hours ago Stock Prices as on Oct 23, 2013 Deccan Herald, 1 month ago Stock Prices as on Oct 18, 2013 Deccan Herald, 1 month ago
Data for 800 companies from Bombay Stock Exchange. Values are: days closing price, previous closing price in brackets, 52-week low and high in bold, and volume traded (in 000) in brackets. GROUP A A A B B 685.8(673.25) 737-448 (49) A C C 1100.8(1094.15) ...Deccan Herald, 2 days ago Stocks as on November 11, 2013 Deccan Herald, 3 weeks ago Stocks as on October 30, 2013 Deccan Herald, 1 month ago Stocks as on Oct 4, 2013 Deccan Herald, 2 months ago
on your WebpageAdd Widget >Get your members hooked!